Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rtPA for CVAD Thrombosis and Infection in Pediatric Short Bowel Syndrome
NCT02355743Phase 4Completed
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4 trial of tissue-plasminogen activator in thrombosis and Infection. Primary endpoint: Development of CVAD Line Thrombosis at 24 weeks. Started Feb 2015; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
thrombosisInfection
Beyond the preview
Go deeper on NCT02355743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355743.